产品
编 号：F302603
分子式：C13H10Cl3N3O4S
分子量：410.66
分子式：C13H10Cl3N3O4S
分子量：410.66
产品类型
规格
价格
是否有货
结构图
CAS No: 276702-15-9
产品详情
生物活性：
SB-332235 is a potent, orally active nonpeptide CXCR2 antagonist, with an IC50 of 7.7 nM. SB-332235 displays 285-fold selectivity for CXCR2 over CXCR1. SB-332235 inhibits acute and chronic models of arthritis in the rabbit. SB-332235 inhibits viability of AML cells.
体内研究：
SB-332235 (25 mg/kg, p.o., b.i.d.) exhibits significantly reduced numbers of total leukocytes in synovial fluids from IL-8-injected knees.SB-332235 (10-25 mg/kg; p.o.; twice a day for 14 days) inhibits chronic Ag-induced arthritis.Animal Model:Adult female New Zealand White rabbits (chronic OVA-induced model of arthritis)
Dosage:10, 25 mg/kg
Administration:P.o.; twice a day for 14 days
Result:Day-15 synovial fluid leukocyte numbers in OVA-injected knees were significantly reduced in rabbits. The decrease in neutrophils, monocytes, and lymphocytes resulting from treatment with 25 mg/kg of the antagonist was accompanied by a significant reduction in synovial fluid PGE2, LTB4, LTC4, and IL-8 levels.
体外研究：
SB-332235 (1-100 μM; 48 hours) inhibits viability of AML cell lines.
SB-332235 is a potent, orally active nonpeptide CXCR2 antagonist, with an IC50 of 7.7 nM. SB-332235 displays 285-fold selectivity for CXCR2 over CXCR1. SB-332235 inhibits acute and chronic models of arthritis in the rabbit. SB-332235 inhibits viability of AML cells.
体内研究：
SB-332235 (25 mg/kg, p.o., b.i.d.) exhibits significantly reduced numbers of total leukocytes in synovial fluids from IL-8-injected knees.SB-332235 (10-25 mg/kg; p.o.; twice a day for 14 days) inhibits chronic Ag-induced arthritis.Animal Model:Adult female New Zealand White rabbits (chronic OVA-induced model of arthritis)
Dosage:10, 25 mg/kg
Administration:P.o.; twice a day for 14 days
Result:Day-15 synovial fluid leukocyte numbers in OVA-injected knees were significantly reduced in rabbits. The decrease in neutrophils, monocytes, and lymphocytes resulting from treatment with 25 mg/kg of the antagonist was accompanied by a significant reduction in synovial fluid PGE2, LTB4, LTC4, and IL-8 levels.
体外研究：
SB-332235 (1-100 μM; 48 hours) inhibits viability of AML cell lines.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备